UBS Global Biopharma Conference 2026
Logotype for IDEAYA Biosciences Inc

IDEAYA Biosciences (IDYA) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for IDEAYA Biosciences Inc

UBS Global Biopharma Conference 2026 summary

16 Nov, 2026

Pipeline and 2026 milestones

  • 2026 brought the first NDA filing, darovasertib Phase III top-line results presented at ASCO, and positive second-line SCLC OS data for the DLL3 TOP1 ADC at ESMO.

  • DLL3 TOP1 ADC advanced into Phase III registrational studies; MTAP and CDKN2A programs were slated for discussion at the London R&D event.

Darovasertib in metastatic uveal melanoma

  • NDA filed in late Q3 under RTOR; filing strategy seeks use irrespective of HLA-A2 status, subject to FDA review. NCCN plans cover HLA-A2-negative and -positive populations.

  • HLA-A2-negative patients were estimated at 60% to two-thirds of the population; >95% of patients were believed to have activating GNAQ/11 mutations, supporting an HLA-independent mechanism rationale.

  • PFS is considered sufficient for accelerated approval based on FDA-aligned endpoints; interim OS readout remained guided for mid-2027, with OS intended as confirmatory evidence.

  • A strong launch was anticipated based on first-line use, no GNAQ/11 diagnostic requirement, and reported PFS hazard ratio and response rate approximately six times the control arm.

  • NCCN guideline process expected to start close to approval and take several months; a 2027 review was considered possible given high unmet need.

PRMT5 and MTAP strategy

  • Clinical data planned for later that day included human PK, safety, pharmacodynamic data, and patient case studies; a potential best-in-class profile was tied to a clean CYP3A4 DDI profile, limited CNS penetration, and MTA-cooperative selective binding.

  • Early clinical combination data with IDE397, another CYP3A4-mediated molecule, were cited as supporting a favorable DDI profile; first dosing with Roche pan-RAS was expected by year-end 2026.

  • Clinical data update targeted for 2027; the initial pan-RAS combination cohort could use the expansion dose, with potentially one cohort and anticipated meaningful activity.

  • Pancreatic cancer was the top combination priority, with frontline PDAC viewed as an open opportunity; the relevant population was estimated at 40%. Lung cancer was also a potential target, with the co-alteration subset estimated at ~5%.

  • CDKN2A candidate IDE101 was expected to enter clinical testing in H1 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from IDEAYA Biosciences